Literature DB >> 31069707

Progressive multifocal leukoencephalopathy in a renal transplant patient.

Tsu-Chen Lin1, Mei-Yi Wu2,3,4,5, Hui-Tzung Luh6,7, Shiou-Fu Lin8, Chien-Min Lin6,7, Ying-Chi Tseng9, Yung-Ching Liu10,11, Mai-Szu Wu12,13.   

Abstract

End-stage renal disease (ESRD) has a major impact on health and affects more than 600,000 people in the USA. The current mainstay treatments include dialysis and kidney transplantation (KT), and patients who have received KT have a higher quality of life and a lower mortality risk than those on chronic dialysis. Therefore, KT is considered the more preferred treatment modality for patients with ESRD. However, even though KT results in a higher long-term survival rate, the use of immunosuppressants is associated with various complications, including opportunistic infections and malignancies, which may lead to a higher risk of death in the first year after transplantation. Progressive multifocal leukoencephalopathy (PML) is a rare complication following KT, with an incidence of 0.027% in KT recipients. We present a case of PML following immunosuppressant therapy in a patient who received KT.

Entities:  

Keywords:  Immunosuppressant agents; JC virus; Kidney transplantation; Progressive multifocal leukoencephalopathy

Mesh:

Substances:

Year:  2019        PMID: 31069707     DOI: 10.1007/s13365-019-00749-8

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  11 in total

1.  Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease.

Authors:  K E ASTROM; E L MANCALL; E P RICHARDSON
Journal:  Brain       Date:  1958-03       Impact factor: 13.501

Review 2.  Imaging manifestations of progressive multifocal leukoencephalopathy.

Authors:  R Shah; A K Bag; P R Chapman; J K Curé
Journal:  Clin Radiol       Date:  2010-06       Impact factor: 2.350

Review 3.  Progressive multifocal leukoencephalopathy in transplant recipients.

Authors:  David Shitrit; Nirit Lev; Ariella Bar-Gil-Shitrit; Mordechai R Kramer
Journal:  Transpl Int       Date:  2004-12-23       Impact factor: 3.782

Review 4.  PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

Authors:  Joseph R Berger; Allen J Aksamit; David B Clifford; Larry Davis; Igor J Koralnik; James J Sejvar; Russell Bartt; Eugene O Major; Avindra Nath
Journal:  Neurology       Date:  2013-04-09       Impact factor: 9.910

Review 5.  Persistence and pathogenesis of the neurotropic polyomavirus JC.

Authors:  Hassen S Wollebo; Martyn K White; Jennifer Gordon; Joseph R Berger; Kamel Khalili
Journal:  Ann Neurol       Date:  2015-03-06       Impact factor: 10.422

Review 6.  Progressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency.

Authors:  S A Misbah
Journal:  Clin Exp Immunol       Date:  2017-03-27       Impact factor: 4.330

Review 7.  Progressive multifocal leukoencephalopathy and other forms of JC virus disease.

Authors:  Bruce J Brew; Nicholas W S Davies; Paola Cinque; David B Clifford; Avindra Nath
Journal:  Nat Rev Neurol       Date:  2010-12       Impact factor: 42.937

Review 8.  Favorable outcome after withdrawal of immunosuppressant therapy in progressive multifocal leukoencephalopathy after renal transplantation: case report and literature review.

Authors:  Hiroya Ohara; Hiroshi Kataoka; Kazuo Nakamichi; Masayuki Saijo; Satoshi Ueno
Journal:  J Neurol Sci       Date:  2014-04-02       Impact factor: 3.181

9.  Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation.

Authors:  Robert T Neff; Frank P Hurst; Edward M Falta; Erin M Bohen; Krista L Lentine; Vikas R Dharnidharka; Lawrence Y Agodoa; Rahul M Jindal; Christina M Yuan; Kevin C Abbott
Journal:  Transplantation       Date:  2008-11-27       Impact factor: 4.939

Review 10.  Progressive multifocal leukoencephalopathy: current treatment options and future perspectives.

Authors:  Dejan Pavlovic; Andriani C Patera; Fredrik Nyberg; Marianne Gerber; Maggie Liu
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.